The failed trial of a drug intended to protect healthy African women against AIDS may be attributed to reluctance to take the pill, researchers said. Last April the trial, involving a pill that would provide small protective doses of anti-retroviral drugs to uninfected people, was halted when it was found that women were still becoming infected. But scientists at an AIDS conference in Seattle this week were told that blood samples from the infected women showed only a quarter of them had any of the drug in their bloodstream, The New York Times reported. It is not known for sure why many women declined to take the drug,Truvada, but AIDS still carries an enormous stigma in Africa and the presence of an AIDS drug in a home might imply someone living there is sick, said Mitchell Warren, executive director of the prevention advocacy group AVAC. Truvada had protected women in another study, he said. The African trial was one of several experimental AIDS treatments presented at the Conference on Retroviruses and Opportunistic Infections.
GMT 13:50 2018 Tuesday ,30 October
Emergency surgery saves life of touristGMT 13:20 2018 Monday ,29 October
National campaign to raise awareness of breast cancerGMT 14:34 2018 Friday ,19 October
Birth spacing "improving health of Omani women"GMT 15:35 2018 Thursday ,11 October
Russia to discuss issue of biological labs near its bordersGMT 16:14 2018 Saturday ,29 September
Premier Khalifa bin Salman congratulated by health ministerGMT 16:10 2018 Saturday ,29 September
Bahrain to host Dermatology, Laser and Aesthetics ConferenceGMT 12:44 2018 Friday ,28 September
EU proposes €40 million for UNRWA to keep health clinics openGMT 07:46 2018 Wednesday ,26 September
HRH Premier to address UN high-level health meetingsMaintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2021 ©
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2021 ©
Send your comments
Your comment as a visitor